We were disappointed to read this yesterday: Pfizer ($PFE) and Johnson & Johnson ($JNJ) have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase…
A recent article in Forbes by ex-Pfizer President or R&D John LaMattina asks a provocative question: Will Pricing Be a Key Differentiator For New Drugs? I recall some 10-15 years…
Our good friend Raman Minhas at ATPBio has a really good post today on the critical factors for a medtech company to be successful using a virtual organizational model. Raman's…
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…
UPDATE (21 February) - Here is a decent video interview of Rachel Sherman, head of the Office of Medical Policy for the FDA, on the Biosimilar guidelines: BioCentury This Week Today…
Last week, the NY Times published an interesting article on the cause of Alzheimer's Disease. The article describes experiments in a new mouse model which may confirm, once and for…
Lacerta Bio was privileged to give a short talk at the first (and hopefully annual) Drug Delivery Summit in London late last month. While lightly attended, the two-day conference brought…
Pharmaceutical outsourcing to CROs is certainly nothing new. However, this week we learned that pharmaceutical giant Lilly and AMRI signed an interesting insourcing / outsourcing agreement. In this deal, AMRI…
Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in…